Serveur d'exploration SDRA et décubitus ventral

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Severe hypoxemic respiratory failure: part 2--nonventilatory strategies.

Identifieur interne : 000316 ( Main/Exploration ); précédent : 000315; suivant : 000317

Severe hypoxemic respiratory failure: part 2--nonventilatory strategies.

Auteurs : Suhail Raoof [États-Unis] ; Keith Goulet ; Adebayo Esan ; Dean R. Hess ; Curtis N. Sessler

Source :

RBID : pubmed:20525656

Descripteurs français

English descriptors

Abstract

ARDS is characterized by hypoxemic respiratory failure, which can be refractory and life-threatening. Modifications to traditional mechanical ventilation and nontraditional modes of ventilation are discussed in Part 1 of this two-part series. In this second article, we examine nonventilatory strategies that can influence oxygenation, with particular emphasis on their role in rescue from severe hypoxemia. A literature search was conducted and a narrative review written to summarize the use of adjunctive, nonventilatory interventions intended to improve oxygenation in ARDS. Several adjunctive interventions have been demonstrated to rapidly ameliorate severe hypoxemia in many patients with severe ARDS and therefore may be suitable as rescue therapy for hypoxemia that is refractory to prior optimization of mechanical ventilation. These include neuromuscular blockade, inhaled vasoactive agents, prone positioning, and extracorporeal life support. Although these interventions have been linked to physiologic improvement, including relief from severe hypoxemia, and some are associated with outcome benefits, such as shorter duration of mechanical ventilation, demonstration of survival benefit has been rare in clinical trials. Furthermore, some of these nonventilatory interventions carry additional risks and/or high cost; thus, when used as rescue therapy for hypoxemia, it is important that they be demonstrated to yield clinically significant improvement in gas exchange, which should be periodically reassessed. Additionally, various management strategies can produce a more gradual improvement in oxygenation in ARDS, such as conservative fluid management, intravenous corticosteroids, and nutritional modification. Although improvement in oxygenation has been reported with such strategies, demonstration of additional beneficial outcomes, such as reduced duration of mechanical ventilation or ICU length of stay, or improved survival in randomized controlled trials, as well as consideration of potential adverse effects should guide decisions on their use. Various nonventilatory interventions can positively impact oxygenation as well as outcomes of ARDS. These interventions may be considered for use, particularly for cases of refractory severe hypoxemia, with proper appreciation of potential costs and adverse effects.

DOI: 10.1378/chest.09-2416
PubMed: 20525656


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Severe hypoxemic respiratory failure: part 2--nonventilatory strategies.</title>
<author>
<name sortKey="Raoof, Suhail" sort="Raoof, Suhail" uniqKey="Raoof S" first="Suhail" last="Raoof">Suhail Raoof</name>
<affiliation wicri:level="2">
<nlm:affiliation>Division of Pulmonary and Critical Care Medicine, New York Methodist Hospital, 506 Sixth St, Brooklyn, NY 11215, USA. sur9016@nyp.org</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Pulmonary and Critical Care Medicine, New York Methodist Hospital, 506 Sixth St, Brooklyn, NY 11215</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Goulet, Keith" sort="Goulet, Keith" uniqKey="Goulet K" first="Keith" last="Goulet">Keith Goulet</name>
</author>
<author>
<name sortKey="Esan, Adebayo" sort="Esan, Adebayo" uniqKey="Esan A" first="Adebayo" last="Esan">Adebayo Esan</name>
</author>
<author>
<name sortKey="Hess, Dean R" sort="Hess, Dean R" uniqKey="Hess D" first="Dean R" last="Hess">Dean R. Hess</name>
</author>
<author>
<name sortKey="Sessler, Curtis N" sort="Sessler, Curtis N" uniqKey="Sessler C" first="Curtis N" last="Sessler">Curtis N. Sessler</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20525656</idno>
<idno type="pmid">20525656</idno>
<idno type="doi">10.1378/chest.09-2416</idno>
<idno type="wicri:Area/Main/Corpus">000315</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000315</idno>
<idno type="wicri:Area/Main/Curation">000315</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000315</idno>
<idno type="wicri:Area/Main/Exploration">000315</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Severe hypoxemic respiratory failure: part 2--nonventilatory strategies.</title>
<author>
<name sortKey="Raoof, Suhail" sort="Raoof, Suhail" uniqKey="Raoof S" first="Suhail" last="Raoof">Suhail Raoof</name>
<affiliation wicri:level="2">
<nlm:affiliation>Division of Pulmonary and Critical Care Medicine, New York Methodist Hospital, 506 Sixth St, Brooklyn, NY 11215, USA. sur9016@nyp.org</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Pulmonary and Critical Care Medicine, New York Methodist Hospital, 506 Sixth St, Brooklyn, NY 11215</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Goulet, Keith" sort="Goulet, Keith" uniqKey="Goulet K" first="Keith" last="Goulet">Keith Goulet</name>
</author>
<author>
<name sortKey="Esan, Adebayo" sort="Esan, Adebayo" uniqKey="Esan A" first="Adebayo" last="Esan">Adebayo Esan</name>
</author>
<author>
<name sortKey="Hess, Dean R" sort="Hess, Dean R" uniqKey="Hess D" first="Dean R" last="Hess">Dean R. Hess</name>
</author>
<author>
<name sortKey="Sessler, Curtis N" sort="Sessler, Curtis N" uniqKey="Sessler C" first="Curtis N" last="Sessler">Curtis N. Sessler</name>
</author>
</analytic>
<series>
<title level="j">Chest</title>
<idno type="eISSN">1931-3543</idno>
<imprint>
<date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adrenal Cortex Hormones (therapeutic use)</term>
<term>Algorithms (MeSH)</term>
<term>Extracorporeal Membrane Oxygenation (MeSH)</term>
<term>Fluid Therapy (methods)</term>
<term>Humans (MeSH)</term>
<term>Hypoxia (etiology)</term>
<term>Hypoxia (therapy)</term>
<term>Neuromuscular Blocking Agents (therapeutic use)</term>
<term>Nitric Oxide (therapeutic use)</term>
<term>Nutritional Support (MeSH)</term>
<term>Phenylephrine (therapeutic use)</term>
<term>Prone Position (MeSH)</term>
<term>Prostaglandins I (therapeutic use)</term>
<term>Randomized Controlled Trials as Topic (MeSH)</term>
<term>Respiration, Artificial (MeSH)</term>
<term>Respiratory Distress Syndrome, Adult (complications)</term>
<term>Respiratory Distress Syndrome, Adult (therapy)</term>
<term>Respiratory Insufficiency (etiology)</term>
<term>Respiratory Insufficiency (therapy)</term>
<term>Vasodilator Agents (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Algorithmes (MeSH)</term>
<term>Curarisants (usage thérapeutique)</term>
<term>Décubitus ventral (MeSH)</term>
<term>Essais contrôlés randomisés comme sujet (MeSH)</term>
<term>Hormones corticosurrénaliennes (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hypoxie (thérapie)</term>
<term>Hypoxie (étiologie)</term>
<term>Insuffisance respiratoire (thérapie)</term>
<term>Insuffisance respiratoire (étiologie)</term>
<term>Monoxyde d'azote (usage thérapeutique)</term>
<term>Oxygénation extracorporelle sur oxygénateur à membrane (MeSH)</term>
<term>Phényléphrine (usage thérapeutique)</term>
<term>Prostaglandines I (usage thérapeutique)</term>
<term>Soutien nutritionnel (MeSH)</term>
<term>Syndrome de détresse respiratoire de l'adulte (complications)</term>
<term>Syndrome de détresse respiratoire de l'adulte (thérapie)</term>
<term>Traitement par apport liquidien (méthodes)</term>
<term>Vasodilatateurs (usage thérapeutique)</term>
<term>Ventilation artificielle (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Adrenal Cortex Hormones</term>
<term>Neuromuscular Blocking Agents</term>
<term>Nitric Oxide</term>
<term>Phenylephrine</term>
<term>Prostaglandins I</term>
<term>Vasodilator Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Respiratory Distress Syndrome, Adult</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Hypoxia</term>
<term>Respiratory Insufficiency</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Fluid Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr">
<term>Traitement par apport liquidien</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Hypoxia</term>
<term>Respiratory Distress Syndrome, Adult</term>
<term>Respiratory Insufficiency</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr">
<term>Hypoxie</term>
<term>Insuffisance respiratoire</term>
<term>Syndrome de détresse respiratoire de l'adulte</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Curarisants</term>
<term>Hormones corticosurrénaliennes</term>
<term>Monoxyde d'azote</term>
<term>Phényléphrine</term>
<term>Prostaglandines I</term>
<term>Syndrome de détresse respiratoire de l'adulte</term>
<term>Vasodilatateurs</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr">
<term>Hypoxie</term>
<term>Insuffisance respiratoire</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Algorithms</term>
<term>Extracorporeal Membrane Oxygenation</term>
<term>Humans</term>
<term>Nutritional Support</term>
<term>Prone Position</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Respiration, Artificial</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Algorithmes</term>
<term>Décubitus ventral</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
<term>Oxygénation extracorporelle sur oxygénateur à membrane</term>
<term>Soutien nutritionnel</term>
<term>Ventilation artificielle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">ARDS is characterized by hypoxemic respiratory failure, which can be refractory and life-threatening. Modifications to traditional mechanical ventilation and nontraditional modes of ventilation are discussed in Part 1 of this two-part series. In this second article, we examine nonventilatory strategies that can influence oxygenation, with particular emphasis on their role in rescue from severe hypoxemia. A literature search was conducted and a narrative review written to summarize the use of adjunctive, nonventilatory interventions intended to improve oxygenation in ARDS. Several adjunctive interventions have been demonstrated to rapidly ameliorate severe hypoxemia in many patients with severe ARDS and therefore may be suitable as rescue therapy for hypoxemia that is refractory to prior optimization of mechanical ventilation. These include neuromuscular blockade, inhaled vasoactive agents, prone positioning, and extracorporeal life support. Although these interventions have been linked to physiologic improvement, including relief from severe hypoxemia, and some are associated with outcome benefits, such as shorter duration of mechanical ventilation, demonstration of survival benefit has been rare in clinical trials. Furthermore, some of these nonventilatory interventions carry additional risks and/or high cost; thus, when used as rescue therapy for hypoxemia, it is important that they be demonstrated to yield clinically significant improvement in gas exchange, which should be periodically reassessed. Additionally, various management strategies can produce a more gradual improvement in oxygenation in ARDS, such as conservative fluid management, intravenous corticosteroids, and nutritional modification. Although improvement in oxygenation has been reported with such strategies, demonstration of additional beneficial outcomes, such as reduced duration of mechanical ventilation or ICU length of stay, or improved survival in randomized controlled trials, as well as consideration of potential adverse effects should guide decisions on their use. Various nonventilatory interventions can positively impact oxygenation as well as outcomes of ARDS. These interventions may be considered for use, particularly for cases of refractory severe hypoxemia, with proper appreciation of potential costs and adverse effects.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">20525656</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>07</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1931-3543</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>137</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2010</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Chest</Title>
</Journal>
<ArticleTitle>Severe hypoxemic respiratory failure: part 2--nonventilatory strategies.</ArticleTitle>
<Pagination>
<MedlinePgn>1437-48</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1378/chest.09-2416</ELocationID>
<Abstract>
<AbstractText>ARDS is characterized by hypoxemic respiratory failure, which can be refractory and life-threatening. Modifications to traditional mechanical ventilation and nontraditional modes of ventilation are discussed in Part 1 of this two-part series. In this second article, we examine nonventilatory strategies that can influence oxygenation, with particular emphasis on their role in rescue from severe hypoxemia. A literature search was conducted and a narrative review written to summarize the use of adjunctive, nonventilatory interventions intended to improve oxygenation in ARDS. Several adjunctive interventions have been demonstrated to rapidly ameliorate severe hypoxemia in many patients with severe ARDS and therefore may be suitable as rescue therapy for hypoxemia that is refractory to prior optimization of mechanical ventilation. These include neuromuscular blockade, inhaled vasoactive agents, prone positioning, and extracorporeal life support. Although these interventions have been linked to physiologic improvement, including relief from severe hypoxemia, and some are associated with outcome benefits, such as shorter duration of mechanical ventilation, demonstration of survival benefit has been rare in clinical trials. Furthermore, some of these nonventilatory interventions carry additional risks and/or high cost; thus, when used as rescue therapy for hypoxemia, it is important that they be demonstrated to yield clinically significant improvement in gas exchange, which should be periodically reassessed. Additionally, various management strategies can produce a more gradual improvement in oxygenation in ARDS, such as conservative fluid management, intravenous corticosteroids, and nutritional modification. Although improvement in oxygenation has been reported with such strategies, demonstration of additional beneficial outcomes, such as reduced duration of mechanical ventilation or ICU length of stay, or improved survival in randomized controlled trials, as well as consideration of potential adverse effects should guide decisions on their use. Various nonventilatory interventions can positively impact oxygenation as well as outcomes of ARDS. These interventions may be considered for use, particularly for cases of refractory severe hypoxemia, with proper appreciation of potential costs and adverse effects.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Raoof</LastName>
<ForeName>Suhail</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Pulmonary and Critical Care Medicine, New York Methodist Hospital, 506 Sixth St, Brooklyn, NY 11215, USA. sur9016@nyp.org</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Goulet</LastName>
<ForeName>Keith</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Esan</LastName>
<ForeName>Adebayo</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hess</LastName>
<ForeName>Dean R</ForeName>
<Initials>DR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sessler</LastName>
<ForeName>Curtis N</ForeName>
<Initials>CN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Chest</MedlineTA>
<NlmUniqueID>0231335</NlmUniqueID>
<ISSNLinking>0012-3692</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009466">Neuromuscular Blocking Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044062">Prostaglandins I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>1WS297W6MV</RegistryNumber>
<NameOfSubstance UI="D010656">Phenylephrine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>31C4KY9ESH</RegistryNumber>
<NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009466" MajorTopicYN="N">Neuromuscular Blocking Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018529" MajorTopicYN="N">Nutritional Support</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010656" MajorTopicYN="N">Phenylephrine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016684" MajorTopicYN="N">Prone Position</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D044062" MajorTopicYN="N">Prostaglandins I</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome, Adult</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>107</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2010</Year>
<Month>6</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>6</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>7</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">20525656</ArticleId>
<ArticleId IdType="pii">S0012-3692(10)60301-7</ArticleId>
<ArticleId IdType="doi">10.1378/chest.09-2416</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>État de New York</li>
</region>
</list>
<tree>
<noCountry>
<name sortKey="Esan, Adebayo" sort="Esan, Adebayo" uniqKey="Esan A" first="Adebayo" last="Esan">Adebayo Esan</name>
<name sortKey="Goulet, Keith" sort="Goulet, Keith" uniqKey="Goulet K" first="Keith" last="Goulet">Keith Goulet</name>
<name sortKey="Hess, Dean R" sort="Hess, Dean R" uniqKey="Hess D" first="Dean R" last="Hess">Dean R. Hess</name>
<name sortKey="Sessler, Curtis N" sort="Sessler, Curtis N" uniqKey="Sessler C" first="Curtis N" last="Sessler">Curtis N. Sessler</name>
</noCountry>
<country name="États-Unis">
<region name="État de New York">
<name sortKey="Raoof, Suhail" sort="Raoof, Suhail" uniqKey="Raoof S" first="Suhail" last="Raoof">Suhail Raoof</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrdaDecubitusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000316 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000316 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrdaDecubitusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:20525656
   |texte=   Severe hypoxemic respiratory failure: part 2--nonventilatory strategies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:20525656" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SrdaDecubitusV1 

Wicri

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 08:17:07 2020. Site generation: Sat Mar 27 13:26:33 2021